C‐reactive protein, a prognostic marker in hepatocellular carcinoma
Jean‐François Dufour – 12 January 2013
Reply:
Sasan Roayaie, Josep Llovet, Myron Schwartz, Vincenzo Mazzaferro – 12 January 2013
αB‐crystallin complexes with 14‐3‐3ζ to induce epithelial‐mesenchymal transition and resistance to sorafenib in hepatocellular carcinoma
Xiao‐Yong Huang, Ai‐Wu Ke, Guo‐Ming Shi, Xin Zhang, Chi Zhang, Ying‐Hong Shi, Xiao‐Ying Wang, Zhen‐Bin Ding, Yong‐Sheng Xiao, Jun Yan, Shuang‐Jian Qiu, Jia Fan, Jian Zhou – 12 January 2013 – The overall survival of patients with hepatocellular carcinoma (HCC) remains poor, and the molecular pathogenesis remains incompletely defined in HCC. Here we report that increased expression of αB‐Crystallin in human HCC predicts poor survival and disease recurrence after surgery.
The role of biopsy of the nontumorous liver parenchyma in patients considered for partial resection of small hepatocellular carcinoma
David Fuks, Francois Durand, Jacques Belghiti – 12 January 2013
Antimitochondrial antibodies may be insufficiently specific to define primary biliary cirrhosis‐like disease in mouse models
Simon Hohenester, Ulrich Beuers, Juan F. Medina, Ronald P. Oude Elferink – 12 January 2013
Reply
M. Eric Gershwin, Patrick S.C. Leung, William M. Ridgway, Ross L. Coppel, Aftab A. Ansari – 12 January 2013
The ART of decision making: Retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma
Wolfgang Sieghart, Florian Hucke, Matthias Pinter, Ivo Graziadei, Wolfgang Vogel, Christian Müller, Harald Heinzl, Michael Trauner, Markus Peck‐Radosavljevic – 12 January 2013 – We aimed to establish an objective point score to guide the decision for retreatment with transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC).
Maternal obesity programs offspring nonalcoholic fatty liver disease by innate immune dysfunction in mice
Angelina Mouralidarane, Junpei Soeda, Clara Visconti‐Pugmire, Anne‐Maj Samuelsson, Joaquim Pombo, Xanthi Maragkoudaki, Adil Butt, Ruma Saraswati, Marco Novelli, Guiseppe Fusai, Lucilla Poston, Paul D. Taylor, Jude A. Oben – 12 January 2013 – The global prevalence of obesity‐induced liver disease (nonalcoholic fatty liver disease; NAFLD) is rising. Suggested causes include a role for in utero influences of maternal obesity compounded by the availability of energy‐dense foods throughout postnatal life.
Hepatocyte nuclear factor 4 alpha deletion promotes diethylnitrosamine‐induced hepatocellular carcinoma in rodents
Chad Walesky, Genea Edwards, Prachi Borude, Sumedha Gunewardena, Maura O'Neil, Byunggil Yoo, Udayan Apte – 12 January 2013 – Hepatocyte nuclear factor 4 alpha (HNF4α), the master regulator of hepatocyte differentiation, has been recently shown to inhibit hepatocyte proliferation by way of unknown mechanisms. We investigated the mechanisms of HNF4α‐induced inhibition of hepatocyte proliferation using a novel tamoxifen (TAM)‐inducible, hepatocyte‐specific HNF4α knockdown mouse model.
A global view of hepatitis C: Physician knowledge, opinions, and perceived barriers to care
Christopher E. McGowan, Ali Monis, Bruce R. Bacon, Josep Mallolas, Fernando L. Goncales, Ioannis Goulis, Fred Poordad, Nezam Afdhal, Stefan Zeuzem, Teerha Piratvisuth, Patrick Marcellin, Michael W. Fried – 12 January 2013 – Chronic infection with the hepatitis C virus (HCV) is a leading cause of global morbidity and mortality. Although recent advances in antiviral therapy have led to significant improvements in treatment response rates, only a minority of infected patients are treated. Multiple barriers may impede the delivery of HCV therapy.